AU2003278816A1 - ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES - Google Patents

ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES

Info

Publication number
AU2003278816A1
AU2003278816A1 AU2003278816A AU2003278816A AU2003278816A1 AU 2003278816 A1 AU2003278816 A1 AU 2003278816A1 AU 2003278816 A AU2003278816 A AU 2003278816A AU 2003278816 A AU2003278816 A AU 2003278816A AU 2003278816 A1 AU2003278816 A1 AU 2003278816A1
Authority
AU
Australia
Prior art keywords
deoxynucleosides
treatment
combination therapies
resistant hbv
hbv strains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003278816A
Other languages
English (en)
Other versions
AU2003278816A8 (en
Inventor
April L. Patty
Maria Seiffer
Jean-Pierre Sommadossi
David Standring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idenix Cayman Ltd
Original Assignee
Idenix Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Cayman Ltd filed Critical Idenix Cayman Ltd
Publication of AU2003278816A1 publication Critical patent/AU2003278816A1/en
Publication of AU2003278816A8 publication Critical patent/AU2003278816A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AU2003278816A 2002-09-13 2003-09-15 ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES Abandoned AU2003278816A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41067502P 2002-09-13 2002-09-13
US60/410,675 2002-09-13
PCT/US2003/029017 WO2004024095A2 (en) 2002-09-13 2003-09-15 ß-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES

Publications (2)

Publication Number Publication Date
AU2003278816A1 true AU2003278816A1 (en) 2004-04-30
AU2003278816A8 AU2003278816A8 (en) 2004-04-30

Family

ID=31994179

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003278816A Abandoned AU2003278816A1 (en) 2002-09-13 2003-09-15 ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES

Country Status (14)

Country Link
US (3) US7186700B2 (https=)
EP (1) EP1572095B1 (https=)
JP (2) JP4173861B2 (https=)
KR (2) KR100855907B1 (https=)
CN (1) CN100536853C (https=)
AU (1) AU2003278816A1 (https=)
BR (1) BR0314259A (https=)
CA (1) CA2498731C (https=)
DK (1) DK1572095T3 (https=)
ES (1) ES2547002T3 (https=)
HU (1) HUE027522T2 (https=)
PT (1) PT1572095E (https=)
SI (1) SI1572095T1 (https=)
WO (1) WO2004024095A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
NZ517929A (en) * 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
EP1572095B1 (en) * 2002-09-13 2015-06-10 Novartis AG Beta-l-2'-deoxynucleosides for use in the treatment of resistant hbv strains
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
HUE029877T2 (en) * 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US8492539B2 (en) * 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CN101171033A (zh) 2005-03-04 2008-04-30 戴纳瓦克斯技术公司 包含具免疫刺激序列iss之寡核苷酸的疫苗：其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定
CN101242857A (zh) * 2005-08-15 2008-08-13 弗·哈夫曼-拉罗切有限公司 用于HBV治疗的PEG-IFNa和利巴韦林
AU2007338899A1 (en) * 2006-12-20 2008-07-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
JP2010520200A (ja) 2007-02-28 2010-06-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド 特定のマトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤を使用する肝疾患を治療する方法
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090082306A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telbivudine
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
CN102140534A (zh) * 2010-12-15 2011-08-03 深圳华大基因科技有限公司 一种hbv基因的核苷酸突变位点的检测方法
RS61447B1 (sr) 2011-04-21 2021-03-31 Glaxo Group Ltd Modulacija ekspresije virusa hepatitisa b (hbv)
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9415065B2 (en) * 2012-04-04 2016-08-16 University Of Central Florida Research Foundation, Inc. Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
JP2016507569A (ja) * 2013-02-07 2016-03-10 トビラ セラピューティクス， インコーポレイテッド ラミブジン結晶塩
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
WO2018092728A1 (ja) 2016-11-16 2018-05-24 国立研究開発法人国立国際医療研究センター 抗ウイルス活性等の生理活性を有するヌクレオシド誘導体
CN111511907A (zh) 2017-03-14 2020-08-07 加利福尼亚大学董事会 对病毒中免疫逃逸功能区域的全基因组鉴定
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
EP4178581A4 (en) 2020-07-07 2024-06-05 Tosk, Inc. URIDINE PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF LUNG DISEASES
CN115607532A (zh) * 2021-07-15 2023-01-17 上海市公共卫生临床中心 大黄酸在制备改善老年机体免疫功能药物中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4916122A (en) 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en) 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
EP0380558A4 (en) 1987-09-22 1991-07-31 The Regents Of The University Of California Liposomal nucleoside analogues for treating aids
EP0712629B1 (en) 1987-10-28 2003-06-18 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
JPH05507279A (ja) 1990-05-29 1993-10-21 ネクススター・ファーマシューティカルズ・インコーポレイテッド グリセロールジ―およびトリホスフェート誘導体の合成
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
IT1246983B (it) 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
KR100270806B1 (ko) 1991-03-06 2000-11-01 템블 존 엘 5-플루오로-2`-데옥시-3`-티아시티딘을 함유하는 b형 간염 치료를 위한 약제
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
AU668873B2 (en) 1991-07-12 1996-05-23 Chimerix, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
JPH08512019A (ja) 1993-03-10 1996-12-17 ザ・ウエルカム・ファウンデーション・リミテッド 免疫反応剤およびキレート化された放射性核種からなるｌ−エナンチオメリックオリゴヌクレオチド複合体を用いる腫瘍ターゲッティング
JP3693357B2 (ja) 1993-04-09 2005-09-07 峯郎 実吉 逆転写酵素阻害剤
WO1994026273A1 (en) 1993-05-12 1994-11-24 Hostetler Karl Y Acyclovir derivatives for topical use
CA2171550C (en) 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides with anti-hepatitis b virus activity
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1996011204A1 (de) 1994-10-07 1996-04-18 Max-Delbrück-Centrum für Molekulare Medizin NEUE β-L-NUCLEOSIDE UND IHRE VERWENDUNG
US5559101A (en) 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
PT831852E (pt) 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
AT409815B (de) 1995-07-11 2002-11-25 Enco En Componenten Ges M B H Anlage zur aufbereitung biogener rohstoffe
US6025335A (en) 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
CA2335617C (en) 1998-06-24 2009-12-15 Novirio Pharmaceuticals Limited Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
JP3959176B2 (ja) * 1998-06-25 2007-08-15 松下電器産業株式会社 ファンモータ駆動装置
PT2415776T (pt) * 1998-08-10 2016-07-07 Novartis Ag Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6065181A (en) * 1998-09-03 2000-05-23 Cleveland; Thomas Portable ticket scratching device with vacuum
AR028149A1 (es) 1999-07-08 2003-04-30 Innogenetics Nv Deteccion de la resistencia a los farmacos contra la hepatitis b
US6265181B1 (en) 1999-09-24 2001-07-24 The Public Health Research Institute Of The City Of New York, Inc. Dosing and development of antimicrobial and antiviral drugs determined by restriction of resistant mutant selection
EA005890B1 (ru) * 2000-05-26 2005-06-30 Айденикс (Кайман) Лимитед СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
MY141594A (en) * 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
WO2002000613A2 (en) * 2000-06-27 2002-01-03 Axxima Pharmaceuticals Ag Inhibitors of hepatitis b virus infection
US6855346B2 (en) * 2001-10-05 2005-02-15 Tzu-Sheng Wu Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
EP1572095B1 (en) * 2002-09-13 2015-06-10 Novartis AG Beta-l-2'-deoxynucleosides for use in the treatment of resistant hbv strains

Also Published As

Publication number Publication date
CN100536853C (zh) 2009-09-09
WO2004024095A3 (en) 2006-02-16
US7186700B2 (en) 2007-03-06
CA2498731A1 (en) 2004-03-25
AU2003278816A8 (en) 2004-04-30
EP1572095B1 (en) 2015-06-10
KR20050051662A (ko) 2005-06-01
PT1572095E (pt) 2015-10-13
US20050080034A1 (en) 2005-04-14
HUE027522T2 (en) 2016-11-28
CN1777363A (zh) 2006-05-24
US8158606B2 (en) 2012-04-17
JP4173861B2 (ja) 2008-10-29
CA2498731C (en) 2012-10-30
JP2006516949A (ja) 2006-07-13
WO2004024095A2 (en) 2004-03-25
SI1572095T1 (sl) 2015-12-31
US20110172178A1 (en) 2011-07-14
EP1572095A4 (en) 2008-11-05
US20080182814A1 (en) 2008-07-31
US7928086B2 (en) 2011-04-19
ES2547002T3 (es) 2015-09-30
BR0314259A (pt) 2005-07-26
KR20080053419A (ko) 2008-06-12
KR100855907B1 (ko) 2008-09-02
EP1572095A2 (en) 2005-09-14
DK1572095T3 (en) 2015-09-14
JP2008273960A (ja) 2008-11-13

Similar Documents

Publication Publication Date Title
AU2003278816A1 (en) ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
AU2002233643A1 (en) Methods of treating diseases in association with decrease in the expression of AOP-1 gene or AOP-1 and remedies for the diseases
AU2003223579A1 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU6910600A (en) Methods for the treatment of mental disorders
AU2003225281A1 (en) Materials and methods for prevention and treatment of rna viral diseases
AU5618501A (en) Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AU6083899A (en) Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU2002364171A1 (en) Materials and methods for the treatment or prevention of obesity
AU2002324649A1 (en) Haplotype map of the human genome and uses therefor
AU5262200A (en) Arrangement in ventilatory treatment of the lungs
AU4511201A (en) Compositions and methods for the induction and treatment of retinal detachments
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU2432001A (en) Treatment of mental conditions including depression
AU2003218834A1 (en) Methods for the treatment and prevention of overweight in mammals
AU5565401A (en) Materials and methods for the treatment of depression
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease
AU2003259689A1 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
AU2003215725A1 (en) Materials and methods relating to the treatment of lymphoma
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase